Charles River Laboratories International (CRL) Economic Moat Analysis38

Moat38

Equal-weight average of four evidence-backed rubric grades (0–4), scaled to 100.

structural advantage · 2/4 · More than 140 research-model stocks and strains, facilities on three continents and broad scientific capabilities support differentiation. However, management's leadership and client-selection assertions do not establish exclusive assets, difficult replication or superior economics relative to competitors. The evidence supports a plausible advantage with uncertain structural protection.

durability · 1/4 · The global operating footprint supports continuity, but demonstrated economic protection is fragile. DSA backlog declined materially in 2023 and stood at $2.0 billion in June 2026 after a modest recovery from year-end 2025. These observations do not prove structural erosion, but provide little evidence of durable insulation from customer spending cycles.

customer dependency · 2/4 · Apollo's more than 18,000 client users, recovering backlog and higher regulated-testing study volume support engagement indirectly. They do not establish customer lock-in or repeat-customer rates. Actual key-customer losses in CDMO demonstrate that relationships can break, although that business was subsequently divested and should not characterize every remaining operation.

erosion resilience · 1/4 · Realized savings and improving backlog provide offsets, but recent operating results show limited insulation: consolidated first-quarter non-GAAP margins fell, and second-quarter DSA margins declined because of higher study costs. These are observed pressures rather than generic risks; sustained resilience against competition or technological substitution remains unestablished.

Pricing power38

Equal-weight average of four evidence-backed rubric grades (0–4), scaled to 100.

realized pricing · 2/4 · Safety Assessment's fiscal 2023 growth explicitly included price increases alongside study volume, demonstrating selective realized pricing ability. The passage does not quantify the price contribution or establish persistence into 2026. Recent DSA organic growth was primarily volume-driven, so it supplies no additional evidence of current price realization.

retention · 2/4 · Engagement evidence is mixed and indirect: Apollo adoption, recovering backlog and higher regulated-testing study volume support continuing demand. Earlier backlog contraction and actual CDMO customer losses offset those positives. No retention rate is inferred, and the subsequent CDMO divestiture limits the relevance of those losses to the current portfolio.

margin resilience · 1/4 · First-quarter 2026 consolidated non-GAAP operating margin fell from 19.1% to 16.3%, reflecting study costs, mix and executive-transition compensation. Second-quarter DSA non-GAAP margin fell from 27.4% to 25.6% because of higher direct costs. Realized savings provide an offset, but observed cost absorption remains weak.

contractual freedom · 1/4 · The disclosed use of fixed-price contracts constrains repricing flexibility, while competition can limit margin maintenance. Historical price increases show some ability to adjust commercial terms, but do not remove those constraints. The risk disclosure establishes contractual exposure without proving that every contract suffered an adverse pricing outcome.

Predictability87

5 consecutive published annual periods. Equal weights: nondeclining revenue frequency; revenue-growth volatility (5–40pp); positive FCF frequency; FCF-margin volatility (3–20pp). Stability indicator, not a growth forecast.

Nondeclining revenue years (%)

50.00

Revenue growth volatility (pp)

5.61

Positive FCF years (%)

100.00

FCF margin volatility (pp)

2.78

observedAnnualPeriods

5.00

Financial strength25

Equal-weight grades: debt/FCF (1–8x), net debt/earnings before interest and tax (0–5x), interest service (1–12x), current ratio (0.75–2x). Earnings use reported operating income, an original issuer-reported unadjusted EBIT reconciled to net income, income tax and signed net interest, or reported pretax profit plus reported gross interest expense. Reported EBIT is distinct from GAAP operating income and gross interest. Interest service uses earnings/interest expense; if unavailable, it uses reported operating cash flow/cash interest paid, without relabeling cash paid as accrued expense. Nonpositive cash flow/earnings score 0 for their service component; reported zero interest with a positive numerator scores 100. Net cash scores 100 for net leverage. Missing disclosures remain unavailable. General nonfinancial-company rubric, not a credit rating; exceptional and nonoperating gains are not normalized out. IFRS finance-cost and cash-flow classifications retain their reported scope.

debtFcfGrade

55.33

netDebtEbitGrade

0.00

interestCoverageGrade

0.00

currentRatioGrade

43.33

Debt / FCF (x)

4.13

Net debt / operating income (x)

76.54

Interest coverage (x)

0.24

Current ratio (x)

1.29

Capital allocation55

Three-year equal-weight indicators: pretax return on average invested capital (0–25%; equity + debt − cash, each year and its prior year), share-count growth (0–5%, lower better), share-based cost/revenue (2–20%, lower better), consolidated FCF/net income (0–1x). Return uses reported operating income, an original issuer-reported unadjusted EBIT reconciled to net income, income tax and signed net interest, or EBIT calculated from reported pretax profit plus reported gross interest expense; the issuer-reported EBIT is distinct from GAAP operating income and gross interest; exceptional/nonoperating gains are not normalized out. Share-based cost uses the reported cash-flow add-back or, if absent, separately reported recognized compensation expense; the latter never becomes an FCF adjustment. Nonpositive net income scores 0 for cash conversion; absent income/FCF stays unavailable. ROIC remains undefined for nonpositive invested capital; the explicit asset-return alternative does not change the ROIC chart. Missing financial inputs alone never trigger an alternative. Does not establish acquisition quality or buyback timing.

3-year pre-tax operating return (%)

5.07

3-year average dilution (%)

-0.81

3-year average SBC / revenue (%)

1.75

cashConversionGrade

0.00

Management50

Equal-weight average of four evidence-backed rubric grades (0–4), scaled to 100.

capital discipline · 2/4 · Fiscal 2025 operating cash generation of $737.6 million supports funding capacity. Against that, the first-quarter 2026 divestiture-related loss of $118.0 million demonstrates an allocation setback, while $300.0 million of first-half repurchases committed substantial capital. The passages do not establish repurchase value creation or returns on recent acquisitions.

incentive alignment · 2/4 · Existing three-year PSUs combine first-year non-GAAP EPS with relative shareholder returns, and the completed 2023 award paid 87.3% of target. Ownership guidelines and anti-hedging safeguards support alignment. A 139% annual bonus alongside weak reported financial outcomes makes the picture mixed; actual ownership compliance is not demonstrated.

execution · 2/4 · More than $175 million of savings benefited fiscal 2025; Apollo adoption, higher regulated-testing volume and backlog recovery demonstrate operating achievements. Recurring restructuring charges, CDMO customer losses and a divestiture loss show material setbacks. This assessment uses disclosed outcomes; the approximately $300 million end-2026 annualized savings target is not treated as achieved.

governance · 2/4 · Disclosed independent committees, Audit Committee qualifications and management's effective disclosure-controls conclusion support established oversight structures. The catalog provides limited evidence of substantive oversight outcomes. Twelve directors were elected subsequently, so the earlier nine-of-eleven independence count is not assumed current. These disclosures support mixed rather than exceptional demonstrated governance.